News

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

  • NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of its previously announced underwritten public offering of an aggregate of 11,250,000 shares of its common stock at an offering price of $4.00 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,750,000 shares of common stock at an offering price of $3.999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and other offering expenses are expected to be approximately $60 million.
    06/13/2024

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

  • NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof). In addition, the Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of its common stock plus the shares of common stock underlying pre-funded warrants sold in connection with the public offering. The public offering is subject to market and other conditions, and there can be no assurance as to whether or when the public offering may be completed or as to the actual size or terms of the public offering. All of the shares in the public offering are being offered by the Company.
    06/13/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Rezolute, Inc. (RZLT) can sell. Click on Rating Page for detail.

The price of Rezolute, Inc. (RZLT) is 3.95 and it was updated on 2024-06-16 07:00:51.

Currently Rezolute, Inc. (RZLT) is in undervalued.

News
    
News

Rezolute to Participate in the Jefferies Global Healthcare Conference

  • REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute, will participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:00 p.m. ET in New York City.
    Thu, May. 30, 2024

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

  • Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention Virtual investor event to be held today at 5:30pm ET REDWOOD CITY, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced positive topline results from the Phase 2 clinical study of RZ402 in patients with DME who are naïve to or have received limited anti-vascular growth factor (anti-VEGF) injections.
    Tue, May. 21, 2024

$DED: What Do We Know So Far?

  • The last few months have seen the Polkadot network come back to life, and ironically, a project called “Dot is Ded” is behind that. Backed by the $DED token, this grassroots memecoin has gone out of its way to get noticed, winning praise and admiration for the way it has leveraged the resilient and never-say-never attitude of the Polkadot community. It’s safe to say that Polkadot is back. Daily trading volume in the past has tipped over $1bn. The community sentiment is absolutely bullish. While the coin price is nowhere near the ATH of the last bull run, optimists and maximalists will argue that there’s nothing stopping them from revisiting a similar price level. Dot is Ded set out with a mission of revitalizing and resurging the Polkadot ecosystem, and while they won’t claim sole responsibility for the recent results, they can be sure that their efforts were a significant catalyst and a bonafide mood changer. They have been helped, in large part, by a mouthwateringly large marketing spend. Almost no new startup in the crypto space has ever had $1m to work with. $DED is built different. With no celebrity backers, no VCs, and just a community team and mission, they had to get creative. This is what DAOs, governance, and treasuries were built for, and so, instead of selling equity for funds, $DED went to Polkassembly and simply asked for some DOT. Here’s the opening statement of their pitch: “Market sentiment is shifting, and several treasuries are actively investing to stimulate growth and excitement during this bull run. For example, Solana’s initiatives, such as $BONK, are leveraging this opportunity effectively. This project’s funding rationale is to capitalize on the memecoin trend as a marketing tool for the DOT ecosystem and to showcase Polkadot’s diversity and buzz-generating capabilities.” It worked. On December 27th, 2023, Polkadot’s DAO voted 61% in favour of releasing 91,557 DOT to the $DED team. At the time, the value was around $8.41 per DOT, but since then the price performed well, peaking at around $10.75. Therefore, the total value of their 91,557 peaked at about $975,000, just shy of $1m. Lunar Strategy, Flight3, and RZLT, the three marketing agencies behind the pitch and now leading an exciting multi-pronged marketing campaign, can revel in the fact that their previous work had already positioned $DED as the leading DOT memecoin. This was crucial to them being selected to bring Polkadot back to life. DOT is DED ($DED), the community-centric memecoin revitalizing the Polkadot ($DOT) network, has listed on the top-10 cryptocurrency exchange MEXC. Users committed 49,939,063 $MX to support the DED listing during MEXC’s Kickstarter campaign. These campaigns help identify high-quality projects and offer free airdrops to users. This centralized exchange listing enhances the legitimacy of DOT is DED, which has already received over $1m from the DOT treasury and distributed $DED to over 1.3m DOT wallet holders via a free airdrop. The $DED listing now exposes it to more than 10 million MEXC customers in 170 countries. MEXC benefits from the active DED community and the fact that many DED holders are also Polkadot supporters. The DED/USDT trading pair opened on MEXC on May 9th at 11:00 (UTC) and saw over $1.7m in trades within the first four days, with the highest volume of $527,800 on May 11th. MEXC, ranking between 10th and 11th in trading volumes with over 2,100 cryptocurrencies, offers $DED a larger ecosystem, aiming to boost trading volumes and engagement. This partnership is crucial for DED’s longevity and success, promoting activity on the Polkadot network. Dot is Ded has been talked about by some of the biggest influencers in the crypto space recently. Take Lark Davis for example, with over 1.1m followers, who shared a tweet of him unstaking his $DOT to make sure it qualifies for the $DED airdrop. This same activity was then shared by AshCrypto to his 1m followers, this time showing exactly how much $DOT he was moving – about $2m worth. That Martini Guy, with 540k followers, told his huge audience exactly how to qualify for the airdrop, with Boxmining (211k) saying “$DED will be THE meme coin on $DOT”. Mando CT (207k) tweeted “I just bought over 3000 $DOT (21,300 USD) from KuCoin and transferred to my wallet to join the $DED Airdrop on Polkadot.”, before shouting out Subwallet, Talisman, and Nova, in another display of ecosystem support. Finally, YouTubers DataDash, DubzyXBT, and CyrilXBT have all also made positive comments about $DED in recent videos. Partnerships, collaborations, grassroots activities – call them what you like, but a common theme that has inspired not just the Polkadot network, but other blockchains too, is how DED has driven people to take action. The community has banded together in style. One poignant example of community involvement is from the Astar Network, which has granted $DED token holders full access to their new game, Astar Strike. They’re also going to redistribute any $DED they get from the airdrop to their own NFT holders – talk about layers! Polkadot wallets and bridges have also gotten involved, in a major way. StellaSwap, a hybrid DEX on Moonbeam, introduced a new DED-DOT feature where users could stake DOT and still qualify for the airdrop. Bitfrost then did the same, building a similar liquid staking feature. Neurolanch and Talisman are running a 350 DOT (~$2800) giveaway in the build-up to $DED’s release, Nova Wallet is giving 20 people 20 DOT each, and Subwallet App is giving 20 people 10 DOT each. The $DED project has breathed new life into the Polkadot network, leveraging community support and strategic marketing to achieve significant milestones. From securing a $1m marketing budget through Polkadot’s DAO to listing on major exchanges like MEXC, Hydradx, and Stellaswap, $DED has proven its impact. Influencer endorsements and strong community partnerships further underscore its success. As $DED continues to stimulate activity within the Polkadot ecosystem, its journey showcases the power of grassroots efforts in the crypto space.
    Mon, May. 20, 2024

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

  • Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
    Wed, May. 15, 2024

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

  • REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study” will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk.
    Tue, Apr. 23, 2024
SEC Filings
SEC Filings

Rezolute, Inc. (RZLT) - 424B5

  • SEC Filings
  • 06/14/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 06/14/2024

Rezolute, Inc. (RZLT) - 424B5

  • SEC Filings
  • 06/13/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 05/31/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 05/28/2024

Rezolute, Inc. (RZLT) - DEF 14A

  • SEC Filings
  • 04/15/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 03/29/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 03/19/2024

Rezolute, Inc. (RZLT) - 4/A

  • SEC Filings
  • 03/18/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 03/18/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 03/14/2024

Rezolute, Inc. (RZLT) - SC 13G

  • SEC Filings
  • 03/11/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 03/11/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 03/08/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 02/28/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 02/27/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 02/21/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 02/20/2024

Rezolute, Inc. (RZLT) - SC 13G/A

  • SEC Filings
  • 02/13/2024

Rezolute, Inc. (RZLT) - SC 13G/A

  • SEC Filings
  • 02/12/2024

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 01/25/2024

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 01/25/2024

Rezolute, Inc. (RZLT) - SC 13G/A

  • SEC Filings
  • 01/18/2024

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 11/30/2023

Rezolute, Inc. (RZLT) - S-3/A

  • SEC Filings
  • 11/22/2023

Rezolute, Inc. (RZLT) - S-3

  • SEC Filings
  • 11/14/2023

Rezolute, Inc. (RZLT) - SC 13G

  • SEC Filings
  • 10/13/2023

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 07/06/2023

Rezolute, Inc. (RZLT) - SC 13D/A

  • SEC Filings
  • 05/03/2023

Rezolute, Inc. (RZLT) - DEFA14A

  • SEC Filings
  • 04/12/2023

Rezolute, Inc. (RZLT) - DEF 14A

  • SEC Filings
  • 04/12/2023

Rezolute, Inc. (RZLT) - SC 13G/A

  • SEC Filings
  • 02/14/2023

Rezolute, Inc. (RZLT) - SC 13G

  • SEC Filings
  • 02/14/2023

Rezolute, Inc. (RZLT) - SC 13G/A

  • SEC Filings
  • 02/13/2023

Rezolute, Inc. (RZLT) - SC 13G/A

  • SEC Filings
  • 02/01/2023

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 11/10/2022

Rezolute, Inc. (RZLT) - S-8

  • SEC Filings
  • 11/07/2022

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 11/07/2022

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 11/04/2022

Rezolute, Inc. (RZLT) - S-3

  • SEC Filings
  • 10/28/2022

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 07/05/2022

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 07/05/2022

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 07/01/2022

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 06/29/2022

Rezolute, Inc. (RZLT) - S-3/A

  • SEC Filings
  • 06/28/2022

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 06/28/2022

Rezolute, Inc. (RZLT) - SC 13G

  • SEC Filings
  • 06/27/2022

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 06/27/2022

Rezolute, Inc. (RZLT) - S-3

  • SEC Filings
  • 06/17/2022

Rezolute, Inc. (RZLT) - 424B5

  • SEC Filings
  • 05/20/2022

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 05/19/2022

Rezolute, Inc. (RZLT) - DEF 14A

  • SEC Filings
  • 05/16/2022

Rezolute, Inc. (RZLT) - 4/A

  • SEC Filings
  • 05/09/2022

Rezolute, Inc. (RZLT) - PRE 14A

  • SEC Filings
  • 05/06/2022

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 05/06/2022

Rezolute, Inc. (RZLT) - 424B5

  • SEC Filings
  • 05/02/2022

Rezolute, Inc. (RZLT) - SC 13G/A

  • SEC Filings
  • 02/14/2022

Rezolute, Inc. (RZLT) - SC 13G/A

  • SEC Filings
  • 02/11/2022

Rezolute, Inc. (RZLT) - SC 13G

  • SEC Filings
  • 12/27/2021

Rezolute, Inc. (RZLT) - SC 13G/A

  • SEC Filings
  • 11/10/2021

Rezolute, Inc. (RZLT) - 424B5

  • SEC Filings
  • 10/14/2021

Rezolute, Inc. (RZLT) - 424B5

  • SEC Filings
  • 10/12/2021

Rezolute, Inc. (RZLT) - 4/A

  • SEC Filings
  • 08/31/2021

Rezolute, Inc. (RZLT) - 424B5

  • SEC Filings
  • 08/04/2021

Rezolute, Inc. (RZLT) - SC 13D

  • SEC Filings
  • 07/28/2021

Rezolute, Inc. (RZLT) - S-8

  • SEC Filings
  • 07/28/2021

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 07/28/2021

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 07/28/2021

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 07/14/2021

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 06/25/2021

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 06/24/2021

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 06/24/2021

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 06/24/2021

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 06/24/2021

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 06/24/2021

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 06/24/2021

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 06/24/2021

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 06/24/2021

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 06/24/2021

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 06/23/2021

Rezolute, Inc. (RZLT) - POS AM

  • SEC Filings
  • 06/21/2021

Rezolute, Inc. (RZLT) - 8-A12B/A

  • SEC Filings
  • 06/21/2021

Rezolute, Inc. (RZLT) - DEF 14A

  • SEC Filings
  • 04/28/2021

Rezolute, Inc. (RZLT) - PRE 14A

  • SEC Filings
  • 04/12/2021

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 03/08/2021

Rezolute, Inc. (RZLT) - SC 13G/A

  • SEC Filings
  • 02/12/2021

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 01/07/2021

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 01/06/2021

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 12/29/2020

Rezolute, Inc. (RZLT) - S-3/A

  • SEC Filings
  • 12/22/2020

Rezolute, Inc. (RZLT) - S-3

  • SEC Filings
  • 12/18/2020

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 11/30/2020

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 11/27/2020

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 11/23/2020

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 11/19/2020

Rezolute, Inc. (RZLT) - S-3

  • SEC Filings
  • 11/13/2020

Rezolute, Inc. (RZLT) - SC 13G

  • SEC Filings
  • 11/10/2020

Rezolute, Inc. (RZLT) - CERT

  • SEC Filings
  • 11/09/2020

Rezolute, Inc. (RZLT) - 3/A

  • SEC Filings
  • 11/05/2020

Rezolute, Inc. (RZLT) - 8-A12B

  • SEC Filings
  • 11/04/2020

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 10/30/2020

Rezolute, Inc. (RZLT) - D

  • SEC Filings
  • 10/22/2020

Rezolute, Inc. (RZLT) - SC 13G

  • SEC Filings
  • 10/14/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 10/14/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 10/08/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 10/07/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 10/05/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 10/02/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/30/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/28/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/25/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/23/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/21/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/18/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/16/2020

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 09/16/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/15/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/14/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/10/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/08/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/04/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/02/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/01/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 08/28/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 08/26/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 08/25/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 08/21/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 08/19/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 08/18/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 08/14/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 08/12/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 08/11/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 08/07/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 08/05/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 08/04/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 08/03/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 07/30/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 07/28/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 07/24/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 07/22/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 07/21/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 07/17/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 07/16/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 07/15/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 07/14/2020

Rezolute, Inc. (RZLT) - SC 13D

  • SEC Filings
  • 03/31/2020

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 03/31/2020

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 03/31/2020

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 12/09/2019

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 12/09/2019

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 12/06/2019

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 12/06/2019

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 12/04/2019

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 12/04/2019

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 11/27/2019

Rezolute, Inc. (RZLT) - S-1

  • SEC Filings
  • 11/18/2019

Rezolute, Inc. (RZLT) - DEF 14A

  • SEC Filings
  • 09/23/2019

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 09/19/2019

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 09/19/2019

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 09/19/2019

Rezolute, Inc. (RZLT) - PRER14A

  • SEC Filings
  • 09/16/2019

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 09/16/2019

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/16/2019

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 09/12/2019

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 09/12/2019

Rezolute, Inc. (RZLT) - S-1/A

  • SEC Filings
  • 09/10/2019

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 09/09/2019

Rezolute, Inc. (RZLT) - PRE 14A

  • SEC Filings
  • 09/06/2019

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 08/26/2019

Rezolute, Inc. (RZLT) - S-1/A

  • SEC Filings
  • 08/19/2019

Rezolute, Inc. (RZLT) - S-1

  • SEC Filings
  • 08/15/2019

Rezolute, Inc. (RZLT) - DEF 14A

  • SEC Filings
  • 04/05/2019

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 04/04/2019

Rezolute, Inc. (RZLT) - PRER14A

  • SEC Filings
  • 03/28/2019

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 03/28/2019

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 03/25/2019

Rezolute, Inc. (RZLT) - CT ORDER

  • SEC Filings
  • 03/18/2019

Rezolute, Inc. (RZLT) - PRE 14A

  • SEC Filings
  • 03/11/2019

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 03/11/2019

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 03/08/2019

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 03/07/2019

Rezolute, Inc. (RZLT) - SC 14F1

  • SEC Filings
  • 01/31/2019

Rezolute, Inc. (RZLT) - CT ORDER

  • SEC Filings
  • 06/25/2018

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 05/17/2018

Rezolute, Inc. (RZLT) - SC 13G

  • SEC Filings
  • 04/30/2018

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 04/30/2018

Rezolute, Inc. (RZLT) - D/A

  • SEC Filings
  • 04/24/2018

Rezolute, Inc. (RZLT) - SC 13D

  • SEC Filings
  • 03/28/2018

Rezolute, Inc. (RZLT) - CT ORDER

  • SEC Filings
  • 03/15/2018

Rezolute, Inc. (RZLT) - D

  • SEC Filings
  • 02/15/2018

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 02/15/2018

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 02/14/2018

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 02/09/2018

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 02/09/2018

Rezolute, Inc. (RZLT) - D/A

  • SEC Filings
  • 02/07/2018

Rezolute, Inc. (RZLT) - S-1

  • SEC Filings
  • 01/29/2018

Rezolute, Inc. (RZLT) - D

  • SEC Filings
  • 01/11/2018

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 11/09/2017

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 11/09/2017

Rezolute, Inc. (RZLT) - S-1/A

  • SEC Filings
  • 11/07/2017

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 11/07/2017

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 11/06/2017

Rezolute, Inc. (RZLT) - S-1/A

  • SEC Filings
  • 10/31/2017

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 10/31/2017

Rezolute, Inc. (RZLT) - DEF 14A

  • SEC Filings
  • 10/20/2017

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 10/13/2017

Rezolute, Inc. (RZLT) - PRER14A

  • SEC Filings
  • 10/13/2017

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 10/13/2017

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 10/11/2017

Rezolute, Inc. (RZLT) - PRE 14A

  • SEC Filings
  • 09/27/2017

Rezolute, Inc. (RZLT) - S-1

  • SEC Filings
  • 09/22/2017

Rezolute, Inc. (RZLT) - D

  • SEC Filings
  • 05/31/2017

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 03/15/2017

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 03/08/2017

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 02/17/2017

Rezolute, Inc. (RZLT) - D

  • SEC Filings
  • 02/14/2017

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 02/13/2017

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 02/09/2017

Rezolute, Inc. (RZLT) - SC TO-I/A

  • SEC Filings
  • 02/03/2017

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 01/24/2017

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 01/20/2017

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 01/20/2017

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 01/20/2017

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 01/18/2017

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 01/17/2017

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 01/17/2017

Rezolute, Inc. (RZLT) - S-1/A

  • SEC Filings
  • 01/13/2017

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 01/13/2017

Rezolute, Inc. (RZLT) - SC TO-I/A

  • SEC Filings
  • 12/27/2016

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 12/22/2016

Rezolute, Inc. (RZLT) - SC TO-I

  • SEC Filings
  • 12/15/2016

Rezolute, Inc. (RZLT) - S-1

  • SEC Filings
  • 12/08/2016

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 11/07/2016

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 10/25/2016

Rezolute, Inc. (RZLT) - POS AM

  • SEC Filings
  • 10/14/2016

Rezolute, Inc. (RZLT) - D

  • SEC Filings
  • 07/13/2016

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 05/17/2016

Rezolute, Inc. (RZLT) - D/A

  • SEC Filings
  • 03/22/2016

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 03/15/2016

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 02/16/2016

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 01/11/2016

Rezolute, Inc. (RZLT) - D

  • SEC Filings
  • 12/21/2015

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 12/21/2015

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 12/17/2015

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 11/16/2015

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 10/27/2015

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 10/23/2015

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 10/23/2015

Rezolute, Inc. (RZLT) - POS AM

  • SEC Filings
  • 10/13/2015

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 08/04/2015

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 07/30/2015

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 07/23/2015

Rezolute, Inc. (RZLT) - S-1/A

  • SEC Filings
  • 07/22/2015

Rezolute, Inc. (RZLT) - S-1/A

  • SEC Filings
  • 07/07/2015

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 07/07/2015

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 06/29/2015

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 06/03/2015

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 06/01/2015

Rezolute, Inc. (RZLT) - S-1

  • SEC Filings
  • 05/22/2015

Rezolute, Inc. (RZLT) - D

  • SEC Filings
  • 04/14/2015

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 03/04/2015

Rezolute, Inc. (RZLT) - D

  • SEC Filings
  • 01/26/2015

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 11/26/2014

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 10/24/2014

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 10/24/2014

Rezolute, Inc. (RZLT) - POS AM

  • SEC Filings
  • 09/30/2014

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 09/10/2014

Rezolute, Inc. (RZLT) - SC 13G

  • SEC Filings
  • 09/09/2014

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 07/25/2014

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 07/24/2014

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 07/03/2014

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 07/02/2014

Rezolute, Inc. (RZLT) - S-1/A

  • SEC Filings
  • 06/25/2014

Rezolute, Inc. (RZLT) - S-1

  • SEC Filings
  • 05/20/2014

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 05/02/2014

Rezolute, Inc. (RZLT) - D/A

  • SEC Filings
  • 04/28/2014

Rezolute, Inc. (RZLT) - D

  • SEC Filings
  • 04/14/2014

Rezolute, Inc. (RZLT) - DEF 14C

  • SEC Filings
  • 04/10/2014

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 04/10/2014

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 04/09/2014

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 04/08/2014

Rezolute, Inc. (RZLT) - PRER14C

  • SEC Filings
  • 04/08/2014

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 04/07/2014

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 04/07/2014

Rezolute, Inc. (RZLT) - PRE 14C

  • SEC Filings
  • 03/31/2014

Rezolute, Inc. (RZLT) - SC 13D

  • SEC Filings
  • 01/24/2014

Rezolute, Inc. (RZLT) - D

  • SEC Filings
  • 01/14/2014

Rezolute, Inc. (RZLT) - RW

  • SEC Filings
  • 12/19/2013

Rezolute, Inc. (RZLT) - S-1/A

  • SEC Filings
  • 11/14/2013

Rezolute, Inc. (RZLT) - S-1

  • SEC Filings
  • 09/30/2013

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 04/18/2013

Rezolute, Inc. (RZLT) - SC 13D

  • SEC Filings
  • 02/11/2013

Rezolute, Inc. (RZLT) - SC 13D

  • SEC Filings
  • 02/08/2013

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 02/08/2013

Rezolute, Inc. (RZLT) - SC 14F1

  • SEC Filings
  • 01/14/2013

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 12/19/2012

Rezolute, Inc. (RZLT) - DEF 14C

  • SEC Filings
  • 12/19/2012

Rezolute, Inc. (RZLT) - PRER14C

  • SEC Filings
  • 12/13/2012

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 12/13/2012

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 12/11/2012

Rezolute, Inc. (RZLT) - PRE 14C

  • SEC Filings
  • 12/03/2012

Rezolute, Inc. (RZLT) - SC 13G/A

  • SEC Filings
  • 10/10/2012

Rezolute, Inc. (RZLT) - SC 13D/A

  • SEC Filings
  • 09/14/2012

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 09/06/2012

Rezolute, Inc. (RZLT) - 4

  • SEC Filings
  • 06/13/2012

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 05/16/2012

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 02/16/2012

Rezolute, Inc. (RZLT) - SC 13G

  • SEC Filings
  • 02/14/2012

Rezolute, Inc. (RZLT) - SC 13D

  • SEC Filings
  • 02/14/2012

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 11/15/2011

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 09/28/2011

Rezolute, Inc. (RZLT) - 3

  • SEC Filings
  • 09/19/2011

Rezolute, Inc. (RZLT) - 8-A12G

  • SEC Filings
  • 09/09/2011

Rezolute, Inc. (RZLT) - EFFECT

  • SEC Filings
  • 08/15/2011

Rezolute, Inc. (RZLT) - 424B3

  • SEC Filings
  • 08/15/2011

Rezolute, Inc. (RZLT) - S-1/A

  • SEC Filings
  • 08/11/2011

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 08/11/2011

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 08/10/2011

Rezolute, Inc. (RZLT) - S-1/A

  • SEC Filings
  • 08/08/2011

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 08/05/2011

Rezolute, Inc. (RZLT) - S-1/A

  • SEC Filings
  • 07/20/2011

Rezolute, Inc. (RZLT) - CORRESP

  • SEC Filings
  • 07/20/2011

Rezolute, Inc. (RZLT) - UPLOAD

  • SEC Filings
  • 07/11/2011

Rezolute, Inc. (RZLT) - S-1

  • SEC Filings
  • 06/14/2011

Rezolute, Inc. (RZLT) - D

  • SEC Filings
  • 05/17/2011
Press Releases
StockPrice Release
More Headlines
News

Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?

  • Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio.
  • 04/15/2024

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

  • Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism)
  • 03/06/2024

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

  • Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
  • 02/13/2024

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

  • REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, to its leadership team as Chief Financial Officer as well as the grant of share options as a material inducement for his appointment (the “Inducement Grant”).
  • 01/24/2024

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

  • REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine designation, the Innovation Passport, to RZ358 for the treatment of hypoglycemia due to congenital hyperinsulinism (HI). The Innovation Passport designation was granted based on the substantial unmet medical need in this condition and the potential for RZ358 to benefit patients as evidenced by the Phase 2 RIZE study in congenital HI, which safely demonstrated significant improvements in hypoglycemia events.
  • 01/23/2024

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

  • Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025 Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025
  • 12/14/2023

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

  • REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of enrollment in its RZ402 Phase 2 study in diabetic macular edema (“DME”).
  • 12/13/2023

Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"

  • Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday Biotech Sale: 12 Stocks for XBI-MAS." Despite overall market health, biotech stocks have significantly declined, with the XBI biotech index 56% lower than its 5-year high, and 30% of NASDAQ-listed biotech companies trading at negative enterprise value.
  • 11/24/2023

Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day

  • REDWOOD CITY, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the management team will participate in BTIG's 3rd Annual Ophthalmology Day, taking place virtually on November 27th.
  • 11/17/2023

Rezolute Reports First Quarter Fiscal 2024 Results

  • REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023.
  • 11/13/2023

Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study

  • Rezolute is a clinical-stage biotechnology company focused on metabolic diseases related to glucose control. Their lead asset, RZ358, is a monoclonal antibody being developed as a treatment for hyperinsulinism, a condition characterized by excessive insulin production. The Company is trading for 50% of cash, about to initiate a phase 3 study in an ultra-orphan indication, with significant potential upside on a valuation basis.
  • 11/09/2023

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

  • PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism
  • 10/17/2023

Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism

  • REDWOOD CITY, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced results following administration of RZ358 to a patient with refractory hypoglycemia due to tumor-mediated hyperinsulinism (tmHI) on a compassionate-use basis, under its expanded access program (EAP).
  • 10/11/2023

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

  • Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023 Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023
  • 09/14/2023

Rezolute to Participate in Upcoming Investor Conferences in September

  • REDWOOD CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder, will participate in two upcoming investor conferences.
  • 09/06/2023

Rezolute to Present at the Jefferies London Healthcare Conference

  • REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder, will participate in a fireside chat at the Jefferies London Healthcare Conference on Thursday, November 17, 2022, at 11:25 a.m. EST/4:25 p.m. GMT.
  • 11/01/2022

Rezolute, Inc. (RZLT) Upgraded to Buy: Here's Why

  • Rezolute, Inc. (RZLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  • 09/21/2022

Rezolute (RZLT) Posts Positive Data From Congenital HI Study

  • Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.
  • 03/24/2022

Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering

  • REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the pricing of an underwritten public offering of 6,030,847 shares of its common stock at a public offering price of $6.50 per share and of pre-funded warrants to purchase 1,661,461 shares of its common stock at a public offering price of $6.49 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each pre-funded warrant.
  • 10/13/2021

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering

  • REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, and, in lieu of common stock, Rezolute intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock. Concurrently with the public offering and by means of a prospectus supplement and accompanying prospectus, Rezolute is offering to sell shares of its common stock directly to certain institutional investors that are current shareholders, in a registered direct offering.
  • 10/12/2021

Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021

  • Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinism
  • 09/22/2021

Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress

  • REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the fourth quarter and fiscal full year ended June 30, 2021.
  • 09/15/2021

Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

  • Tracking to Announce Top line data in Q1 2022
  • 09/09/2021

Rezolute to Participate in Upcoming Virtual Healthcare Conferences

  • REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, today announced that Nevan Charles Elam, CEO and Founder, will present at two upcoming virtual investment conferences.
  • 09/07/2021

Rezolute Added to Russell Microcap® Index

  • REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, has been added to the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28.
  • 06/28/2021

5 Stock Gainers For May 27: VTNR, GOED, RZLT, AMC, RVPH

  • Here is an overview of 5 of the top stock gainers for May 21 and why the stock prices moved. The post 5 Stock Gainers For May 27: VTNR, GOED, RZLT, AMC, RVPH appeared first on Pulse 2.0.
  • 05/27/2021

RZLT Stock Price: Over 85% Increase Explanation

  • The stock price of Rezolute Inc (NASDAQ: RZLT) increased by over 85% during intraday trading. This is why it happened.
  • 05/27/2021

Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs

  • REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the addition of Davelyn Hood, MD, to its leadership team as Director, Scientific and Patient Affairs. In her new role, Dr. Hood will be a key member of the team in furthering the development of RZ358, Rezolute's monoclonal antibody currently being evaluated in a Phase 2b clinical trial to treat congenital hyperinsulinism, a rare disease that is the most common cause of persistent low blood sugars in children.
  • 05/20/2021

Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit

  • REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalance, today announced that management will present at the Oppenheimer Rare and Orphan Disease Summit. The presentation will be available on-demand starting at 8:00 AM ET on Friday, May 21, 2021.
  • 05/17/2021

Rezolute to Participate in Upcoming Investor Conferences in March

  • REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company's CEO and Founder, will be presenting at the following upcoming investor conferences:
  • 03/02/2021

Rezolute Reports Second Quarter Fiscal 2021 Financial Results

  • REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020.
  • 02/10/2021

Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

  • RZ402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for DME
  • 01/12/2021
Unlock
RZLT Ratings Summary
RZLT Quant Ranking